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Abstract
Innovations in antiretroviral (ARV) treatment strategies have resulted in treated HIV-infected
patients having life expectancies similar to those of uninfected individuals. Yet the number of
individuals capable of HIV transmission is increasing—for every person in whom ARV treatment
is initiated, four others are becoming newly infected with HIV. The limited progress with
microbicides and vaccines for HIV prevention reinforce the need for a concentrated exploration of
the utility of ARVs. Preliminary animal studies with topical and systemic ARVs show promising
results. However, current clinical trials were designed without a comprehensive understanding of
ARV pharmacokinetic–pharmacodynamic relationships in HIV prevention. This review focuses
on current strategies for the prevention of HIV infection and on the ways in which the tools of
pharmacology can be a valuable resource for determining pharmacodynamic targets, providing
interspecies scaling of exposures, identifying the optimal drugs/drug combinations, doses, and
dosing regimens, and designing efficient clinical trials.
Over the past 10 years, innovations in antiretroviral (ARV) treatment strategies have
resulted in treated HIV-infected patients having similar life expectancies as their uninfected
counterparts.1 Yet the number of individuals capable of HIV transmission is increasing.
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), the number of
newly infected individuals worldwide in 2008 was ~2.7 million.2 Since the early 1990s,
transmission rates have been relatively stable in the United States.3 This is attributable, in
part, to increased efforts in carrying out HIV screening, placing patients into care, and
promoting behavior-modifying interventions.4 However, countries that lack access to
resources have not had similar success. For example, between 2001 and 2008, in the Middle
East and North Africa, the number of newly infected individuals increased by 17%, and the
number of adult and child deaths caused by AIDS increased by 80%.2 The World Health
Organization estimates that for every person in whom ARV treatment is initiated, four
others are newly infected with HIV.5 Because current treatment interventions are not likely
to curb the HIV epidemic, other prevention efforts are desperately needed.
As illustrated in Figure 1, interventions for HIV prevention can be divided into four main
strategies based on the time course of exposure. In an individual who has yet to be exposed
to HIV, behavioral and structural interventions may be effective.4 In an exposed individual
at the time of coital exposure, a vaccine that provides neutralizing antibodies or a pre-
exposure prophylaxis (PrEP) intervention with topical microbicides/ARVs or with systemic
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ARVs may be effective. In an exposed individual shortly after the time of exposure, a
vaccine or a postexposure prophylaxis (PEP) intervention with ARVs may be effective.
Once infected, an individual may be rendered less infectious if placed on potent combination
ARV therapy.6,7
The efficacy of each of the aforementioned interventions depends on the type and timing of
the intervention. Strategies that reduce transmission risks, such as male circumcision and
condom use, along with other behavior-modifying interventions, have shown 50–80%
efficacy in clinical trials.8 However, achieving consistent implementation of these practices
remains a challenge, particularly given the social and cultural conditions that can preclude
women from being empowered to insist that their sexual partners adopt these measures.9
Recent advances in vaccine development are encouraging,10 but worldwide implementation
of an effective vaccine is years away. Therefore, it is critical to identify potential
pharmacologic interventions to curtail the HIV epidemic quickly.
These strategies include the use of microbicides and traditional ARV drugs, either
systemically or topically. Typically, microbicides act in the vaginal lumen to either destroy
the virus before it can traverse mucosal surfaces or prevent viral attachment to mucosal
surfaces. This is in contrast to ARVs, which are distributed into tissues following oral or
topical application and act at the mononuclear cellular level to prevent viral entry or
replication. This article provides a brief review of the opportunities regarding pharmacologic
interventions and their roles in the exposure continuum (Figure 1). We also summarize
current obstacles facing the clinical pharmacology of HIV prevention and possible
opportunities to overcome them.
CURRENT APPROACHES TO PrEP AGAINST HIV INFECTION
PrEP involves taking protective measures before an encounter that could lead to HIV
infection. An effective PrEP intervention would be very valuable for sex workers, HIV-
negative partners of HIV-seropositive individuals, and others who are at a high risk of being
exposed to HIV. Both topical and systemic approaches to PrEP have been proposed.
Although four topical microbicide compounds have been evaluated for efficacy, none has
demonstrated protection in randomized placebo-controlled clinical studies.11 The first
microbicide evaluated (Col-1492; a vaginal gel containing nonoxynol-9) unexpectedly
demonstrated higher seroconversion rates (16%) than placebo (12%) in a phase III study
involving 892 female sex workers in four countries.12 Four nonspecific microbicides
(cellulose sulfate, Carraguard, Buffer Gel, and Pro 2000) have failed to demonstrate efficacy
in clinical trials.11 Two additional agents, VivaGel (SPL7013 3%; a membrane-binding
inhibitor) and Amphora (Acidform lubricant; an acidifying vaginal-defense enhancer), are
currently undergoing trials for safety and acceptability. A recent phase I study showed that
when compared to placebo gel (hydroxyethyl cellulose), women who used the active drug
were less adherent (77% vs. 95%) and reported they would be less likely to continue to use
this product (36% vs. 61%).
With the disappointing results of microbicide trials, topical formulations of ARVs are
actively being investigated. Nucleoside/tide analog and non–nucleoside analog reverse-
transcriptase inhibitors (NRTIs and NNRTIs) are of greatest interest because of their
preintegration activity, long (intracellular) half-lives, safety profiles, and success in
preventing infection in animal models.13,14 The attributes of the three leading candidate
drugs are summarized here.
Tenofovir (TFV) is an NRTI that has advanced the furthest in PrEP clinical trials. It has
been approved by the US Food and Drug Administration for HIV treatment since 2001 in
the form of its salt, TFV disoproxil fumurate (TDF), and is often used along with the NRTI
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emtricitabine (FTC). Caprisa 004 was a phase II 24-month safety and efficacy study looking
at coital-dependent use of 1% TFV gel in 900 high-risk South African women. Results of
this randomized, double-blinded trial were announced in July 2010. When applied vaginally
within 12 h before after sex, TFV gel demonstrated a 39% reduction in HIV infection.15
The efficacy of vaginally applied TFV 1% gel has been investigated in a macaque model of
repeated low-dose exposure to a chimeric simian–human immunodeficiency virus
(SHIVSF162P3; 10 50% tissue culture infectious doses or 1.5 × 106 copies RNA per
exposure).16 Three milliliters of TFV 1% gel, TFV 1% + FTC 5% combination gel, or
placebo gel was administered vaginally 30 min before viral challenge in groups of six
macaques. All six of the animals in the TFV and TFV + FTC gel groups remained protected
from infection after 20 weekly viral challenges, whereas only one of the six animals in the
placebo group remained uninfected (P < 0.001). The average plasma TVF concentrations
from these protected animals 30 min after dosing were 16 ng/ml for TFV gel and 39 ng/ml
for TFV + FTC gel. In comparison, preliminary pharmacokinetic data in humans after a 4-g
intravaginal dose of 1% TFV gel demonstrate that blood plasma concentrations >5 ng/ml are
seldom achieved.17
Using male rhesus macaques, Cranage et al. demonstrated that rectal application of 3 ml of
TFV 1% gel up to 2 hours before exposure to simian immunodeficiency virus
(SIVmac251/32H, 20 median rectal infectious doses) prevented infection in six of nine
animals, whereas only one in four of the animals in the placebo group remained
uninfected.18 Analysis of plasma concentrations 15 min after dosing suggested that
protection was associated with higher TFV exposures; the lowest plasma TFV concentration
conferring protection was 120 ng/ml. Currently, the TFV concentration in plasma achieved
in humans after rectal application of TFV 1% gel is unknown. However, assuming that the
average male rhesus monkey weighs 8 kg and an average human is 70 kg, nearly 30 ml of
gel would need to be used in humans in order to achieve the same mg/kg dose.
TFV has also been shown to be safe and efficacious in colorectal and cervical tissue
explants.19,20 After a 1-h drug incubation, colorectal tissue demonstrated 100% protection
from infection (2-h exposure to 30× the tissue culture ID50 HIVBaL) at concentrations of 10
and 100 μg/ml and >90% inhibition at concentrations of 0.1 and 1 μg/ml.19 In a polarized
cervical explant culture (in which only the epithelial layer is exposed to the air interface),
the application of a 1-mg/ml TFV gel reduced p24 antigen concentrations from an HIVBaL
inoculation by 1 log as compared with untreated explants.20
UC871 is an NNRTI with an intracellular half-life of 5.5 days.21 This long half-life confers
protection against HIV infection in explant culture models up to 6 days after initial drug
exposure.21 In colorectal explants, complete protection from HIVBaL infection was seen at
UC781 concentrations ranging from 10 to 100 μmol/l.19 In cervical explant tissue, 100
μmol/l UC781 was able to confer complete protection from a 2-h exposure to HIVBaL. At
concentrations as low as 1 nmol/l, >99% protection was seen.22 Using 20 pig-tailed
macaques, and on the basis of in vitro toxicity assays, colposcopy examination, rectal lavage
examinations, and measurements of rectal pH and rectal microflora, Patton et al. concluded
that UC781 0.1% and 1% gel formulations were safe as four daily doses of rectal (2.5 ml) or
vaginal (1.5 ml) application.23 Even with repeated dosing, UC781 was not detected in the
plasma of the animals, thereby suggesting minimal systemic absorption. Up to 6 h after
administration of 1% gel, vaginal lavage samples contained UC781 concentrations above the
half-maximal inhibitory concentration, but by 24 h, they were undetectable. UC781 has
completed phase I safety trials, and phase II trials for rectal and vaginal use are planned
(http://www.conrad.org).
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Dapivirine (TMC120) is a second-generation NNRTI that maintains efficacy against many
NNRTI-resistant strains of HIV.24 Although dapivirine’s poor bioavailability precludes its
use in oral dosing, its potential to achieve high local concentrations in a topical formulation
may prove advantageous. In a cervical explant model, the absence of detectable proviral
DNA with dapivirine exposure ≥0.001 μmol/l demonstrated its potential efficacy in
preventing HIV infection.25 At concentrations of 1–10 μmol/l, dapivirine demonstrated a
protective effect against HIV-1 infection for ≤6 days after drug exposure. Pharmacokinetic
evaluations performed after 7 days of vaginally administered [14C]dapivirine 0.009% gel
(0.5 ml/day in rabbits and 1 ml/day in macaques) demonstrated low-to-undetectable plasma
concentrations, with cervical and vaginal tissue concentrations being greater than the in vitro
EC90 (0.9 ng/ml) value for up to 48 h after dosing.26,27 Histopathological analyses of tissues
from both species demonstrated that most of the drug remains on the mucosal surface,
within the keratinized layer of the epithelium, or in compromised areas of tissue and rarely
extends into the submucosa. Because compromised areas (lesions, ulcers, etc.) are often
portals for HIV entry, this phenomenon could be clinically important. In two clinical studies,
2.5 ml dapivirine gel concentrations of 0.001, 0.002, 0.005, and 0.02% were administered
twice daily for 42 days in healthy, HIV-negative women.28 Adherence was >90% based on
applicator count and, although sample timing in relation to gel application was not reported,
mean (s.d.) concentrations in plasma on day 42 were 17.9 (15.2), 42.4 (29.0), 76.7 (58.3),
and 427 (215) pg/ml, respectively. Dapivirine has also been developed into a vaginal ring
delivery system; this controlled drug-release system and longer dwell time may have the
advantage of facilitating better adherence to the regimen, thereby enabling more effective
HIV prophylaxis. In a phase I study, two different intravaginal ring (IVR) delivery systems
(matrix and reservoir) containing 25 mg of dapivirine were evaluated for safety and
pharmacokinetic exposure.27 The release of the drug varied greatly between the two rings.
In the reservoir IVR, only ~600 μg was released over a 28-day period as compared with
10.5 mg released from the matrix IVR. Although the matrix IVR produced plasma
concentrations 50-fold that of the reservoir IVR (maximum plasma concentration (Cmax)
1,194 vs. 51.87 pg/ml), both rings produced vaginal fluid concentrations above dapivirine’s
EC50 of 0.3 ng/ml for the entire 28 days of the study and for at least 5 days after removal
(Cmax 7.5–14.37 μg/g for reservoir IVR and 850–1,900 μg/g for matrix IVR).
Although topical formulations of ARVs allow high local exposure while limiting systemic
exposure, restrictions to their use may include: difficulty in application, problems with
adherence to the regimen, lack of acceptance by user and partner, local irritation, and the
necessity for multiple applications per encounter if multiple mucosal surfaces require
protection. Systemic dosing of ARVs provides an alternative approach for protection and
may overcome some of these challenges. Identifying an effective prophylactic pill that
women can take outside the setting of sexual intercourse precludes the necessity to disclose
such use to their partners, thereby empowering the women.
Currently, the target drug exposure required for preventing HIV infection at mucosal
surfaces is unknown. Therefore, the current assumption is that higher drug exposures are
better at conferring protection. However, ARVs differ greatly in their ability to penetrate
mucosal tissues or secretions.29–33 Generally, highly protein-bound compounds do not gain
access to these secondary compartments because of their affinity for plasma proteins such as
albumin and a1-acid glycoprotein. Drugs such as the protease inhibitors, which are 95–99%
bound to plasma proteins, achieve female genital tract concentrations <50% those in the
plasma.32 In contrast, most NRTIs have a low degree of protein binding (<0.7–49%) and
achieve concentrations two-to sixfold higher in mucosal tissue than in plasma.32 However,
protein binding is not the only predictor of ARV exposure. For example, maraviroc, a
cellular entry inhibitor that demonstrates 85% plasma protein binding, has high penetration
into cervicovaginal fluid (CVF) and vaginal tissue. After 7 days of dosing at 300 mg of
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maraviroc twice daily, the areas under the concentration–time curve (AUCs) in CVF and
vaginal tissue are 2.7 and 1.9 times higher, respectively, than that in plasma.30 Raltegravir,
an integrase inhibitor that is 83% protein bound in plasma, has also been shown to penetrate
well in the genital tract: the concentrations of the drug in CVF after multiple dosing are
approximately equal to those in plasma.33 Currently, there are no published data regarding
intrasubject pharmacokinetic variability in the female genital tract: there have been no
studies sampling the same individuals under steady-state conditions over multiple days.
However, the intersubject variability of drug exposure in the female genital tract is generally
greater than in plasma (the coefficients of variation range ~50–200% in CVF and 2–100% in
plasma).
An additional matter to be considered relating to ARV pharmacokinetics and
pharmacodynamics at mucosal surfaces is protein binding within the mucosal secretions.
The concentrations of albumin and a1-acid glycoprotein in CVF are <1% of the values in
plasma.34 Although the protein binding of drugs in genital secretions has not been
extensively evaluated, maraviroc has recently been shown to have tenfold less protein
binding in CVF than in plasma (7.5% vs. 75%).30 This phenomenon must be considered in
pharmacokinetic–pharmacodynamic analysis of ARV prevention strategies.
The extent of penetration of drugs into rectal tissues also has implications for HIV
transmission. Exposures (AUC12 h) of maraviroc are ~30 times higher in rectal tissues than
in plasma.31 Some drugs, such as the nucleoside/tide analogs, require cellular uptake and
phosphorylation in order to be active against the reverse-transcriptase enzyme. Intracellular
and extracellular concentrations of TFV and FTC have been recently evaluated in plasma
and in cervical, vaginal, and rectal tissues after a single dose.35 Sampling was performed at
time points from 24 h to 14 days after the dose. TFV exposures (as measured by
AUCday 1–14) were 5.8, 0.6, and 34 times higher in cervical, vaginal, and rectal tissues,
respectively. FTC exposures were 41, 7, and 4.4 times higher in cervical, vaginal, and rectal
tissues, respectively. Intracellular concentrations of TFV diphosphate were detected in all
tissues for at least 7 days. FTC triphosphate was detected in tissues only for 2 days after
dosing despite peripheral blood mononuclear cell concentrations persisting for 10 days.
These initial tissue data suggest that these ARVs may be promising candidates for HIV
prevention. However, more comprehensive pharmacokinetic data are required in order to
guide drug development.
Several systemically dosed ARVs have been tested for PrEP efficacy in nonhuman primates
and humanized mice. Oral dosing of CMPD167, a CCR5 inhibitor, prevented infection from
vaginal exposures to SHIV162P3 in 50% (10/20) of macaques when treatment with the drug
was continued for 10 days after exposure and in 25% of the animals (one in a group of four
animals) when the drug was given only for 4 days before exposure.36
Subbarao et al. demonstrated that with weekly exposure to low-dose SHIV (3.8 × 105 viral
particles per exposure) in the rectum, oral daily (n = 4) or weekly (n = 4) doses of 22 mg/kg
TDF can delay time to infection by 4.5–5.5 weeks and provide a 60% lower per-exposure
probability of infection.37 In this model, viral inoculation was performed 2 h after TFV
administration: this time point was selected on the basis of pharmacokinetic sampling in a
single macaque, which showed a concentration of 633 ng/ml at 2 h after the dose. Single
samples of plasma in these macaques at 2 h after the dose revealed lower TFV exposures
(10–137 ng/ml) in 80% of the macaques (four of the five animals tested) that were infected
as compared with those that were protected (mean value 2,000 ng/ml). In 2008, Garcia-
Lerma et al. evaluated five different routes, combinations, and/or schedules of TFV and FTC
in a rectal, low-dose SHIV (7.5 × 105 viral particles per exposure) repeat-exposure macaque
model.38 Oral doses were selected on the basis of preliminary pharmacokinetic dose-ranging
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analyses in 11 animals (5 for TDF and 6 for FTC),demonstrating AUCs similar to those in
humans at doses of 20–24 mg/kg of TDF and 20 mg/kg of FTC (AUCs for TFV were 3.2–
3.4 μg · h/ml, within the range related to humans, of 1.03–3.56 μg · h/ml; AUC for FTC was
13.2 μg · h/ml in macaques and ~10 μg · h/ml in humans; ref. 32). In this investigation,
complete protection from HIV infection was achieved with daily subcutaneous dosing of
TVF 22 mg/kg and FTC 20 mg/kg. Other daily regimens (subcutaneous FTC 20 mg/kg
alone or oral TDF 22mg/kg + FTC 20 mg/kg) achieved only partial protection (33 and 67%,
respectively).
Daily intraperitoneal doses of the combination of TDF + FTC (5.2 + 3.5 mg) also proved to
be protective in a humanized BLT mouse model. All five mice in the group were given FTC
+ TDF daily beginning 2 days before, and continuing for 7 days after, vaginal inoculation
with ~9 × 104 tissue culture infectious units of HIV-1 JRCSF. All remained infection-free,
as compared with only one of the eight animals in the control group.39 This regimen was
also tested in models of rectal and intravenous transmission of HIV. After intraperitoneal
injections every day for 3 days, the animals were exposed to HIV-1JRCSF in the rectal
mucosa or by intravenous injection while continuing to receive daily TDF + FTC for an
additional 4 days.40 Under this regimen, no infections were noted with rectal challenge (n =
9), and only one animal was infected with intravenous challenge (n = 9). As in macaques,
pharmacologic data on these doses in mice are lacking. Calculated using weight-based
scaling, intraperitoneal doses of ~30 mg/kg were administered to these mice, which far
exceeds the ~4 mg/kg being used in current PrEP clinical trials.
Despite the sparseness of pharmacokinetic data from studies in humans and the
pharmacologic limitations of the data from studies in animals, a number of clinical studies
were initiated in multiple at-risk populations with standard dosing of TFV with or without
FTC. Table 1 provides details of these PrEP investigations; the results from at least four of
these investigations are expected to be released in 2010. Although all of these studies are
using daily dosing in the investigation, this regimen may not be practical for individuals who
are only occasionally exposed to high-risk encounters. In this situation, daily dosing may
result in decreased rates of adherence to medication regimens (prophylaxis fatigue) and
unnecessary systemic toxicity. Therefore, intermittent PrEP (iPrEP), using dosing either
related or unrelated to the occurrence of coitus, is also being investigated.
Several ARVs have pharmacokinetic profiles that are favorable for iPrEP. The
pharmacokinetics of maraviroc, TFV, and FTC have been discussed in detail previously.
Maraviroc also has a long residence time in the genital tract, remaining at levels higher than
the protein-free half-maximal inhibitory concentration in CVF for at least 72 h after a
dose.30 TFV and FTC also have extended pharmacokinetic profiles in mucosal surfaces after
a single dose.29,32 An analysis of blood and rectal cells in macaques after oral TDF + FTC
(20 + 22 mg/kg) revealed long intracellular half-lives for TFV diphosphate (78–170 h) and
FTC triphosphate (15–49 h).41 Interestingly, despite the presence of TFV diphosphate in
rectal mononuclear cells at 2 h after the dose, FTC triphosphate was not detected until 24 h
after the dose. The explanation for this finding is still under investigation.
With the use of these drugs, iPrEP has shown positive results in some investigations in
animals. For example, all six of the macaques that were treated with subcutaneous TFV +
FTC (22/20 mg/kg) 2 h before and 24 h after repeated low-dose SHIV exposures in the
rectum were protected from infection for >14 weeks.38 A recent investigation has
demonstrated maximum protection from 14 weekly SHIV exposures when a subcutaneous
pre-exposure dose 22 h before exposure is followed by a postexposure dose at 2 h after the
exposure (hazard ratio 16.7) (ref. 41). This protection decreases when the pre-exposure dose
is administered as early as 3 and 7 days before infection (hazard ratio 15.4 and 9.3,
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respectively) or if the postexposure dose is delayed by 22 or 26 h after the infection (hazard
ratio 4.1 and 4, respectively).
Before a clinical trial for iPrEP can be performed, thorough extracellular and intracellular
pharmacokinetic analyses must be performed with these agents to allow optimal interspecies
scaling from humanized mice, to macaques, to humans. Although it is not known whether
the pharmacokinetic–pharmacodynamic relationship with ARVs and HIV prevention is
similar among these species, it would be useful to assure at least similar ARV exposures.
HPTN 066 is a multisite phase I study scheduled to begin in 2010. This study will involve
four different treatment regimens in HIV-negative men and women (arm 1: 300 mg TDF/
200 mg FTC weekly; arm 2: 300 mg TDF/200 mg FTC twice weekly; arm 3: 600 mg TDF/
400 mg FTC twice weekly; and arm 4: 300 mg TDF/200 mg FTC daily). Sampling of rectal,
seminal, and vaginal fluids, plasma, cells, and tissues will be performed to assess the dose-
proportionality of intracellular phosphorylated metabolites of TFV and FTC and to quantify
their intraindividual variability. The information from this study will fill a large gap in the
knowledge of intracellular kinetics of these medications at multiple mucosal surfaces and
will help identify the time periods during which specific dosing strategies confer protection.
Quantification of the intraindividual variability will enable future studies to use drug
concentrations as a determinant of adherence to medication regimens.
Finally, a preliminary clinical study in Kenya and Uganda is currently under way among 150
serodiscordant couples to evaluate the safety and acceptability of iPrEP (http://
www.iavi.org). In this investigation, subjects will take standard doses of oral TDF/FTC once
daily or intermittently (defined as twice weekly plus coitus-related dosing). Samples for
blood plasma and intracellular concentrations will be obtained.
CURRENT APPROACHES TO PEP
PEP involves prevention of HIV infection after a known or suspected exposure in a health-
care worker (occupational PEP) or a sexual encounter associated with risk of infection
(nonoccupational PEP; nPEP). Guidelines and recommendations for occupational and nPEP
come from small studies, case reports, and data from animal studies. Adequately powered
interventional clinical trials are prohibitively expensive, given the low HIV-infection rates
and the need for an active control arm. Current Centers for Disease Control and Prevention
guidelines (updated in 2005—http://www.cdc.gov/hiv/resources/guidelines/index.htm) for
occupational PEP use an algorithm based on type of exposure and the infection status of the
source. Although dual or triple combination therapy is superior to monotherapy for the
treatment of HIV infection, there is no evidence that this superiority holds true for PEP.
However, on the basis of data from animal studies, 4 weeks of therapy is recommended.42
The selection of a regimen is largely empirical and based on potency and durability data
from treatment studies. Preferred regimens involve one or two nucleoside analogs
(zidovudine: ZDV, lamivudine: 3TC, FTC, or TDF) with a protease inhibitor (lopinavir/
ritonavir) or efavirenz.
One case–control study investigating seroconversions of health-care workers after
needlestick injury demonstrated that, after controlling for other factors (e.g., deep injury,
visible blood on the needle, and terminal illness of the source) the use of ZDV reduced the
risk of infection by 81% (adjusted odds ratio = 0.21, P = 0.002) (ref. 43). This provides
important proof of concept for utilizing ARVs in a PEP setting.
Nonoccupational exposures include those that involve the male and female genital tracts, the
rectal mucosa, and exposure from intravenous drug use. Historically, the use of nPEP has
been less consistent than occupational PEP because the benefit of the routine use of the
former has been debated. One major concern is behavioral disinhibition. The potential for
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increase in risky behaviors with increased availability of nPEP has been both supported and
refuted in observational studies.29 However, studies and case reports have supported the
feasibility of nPEP,29 and, in 2005, the Centers for Disease Control and Prevention issued
recommendations for its use (http://www.cdc.gov/hiv/resources/guidelines/index.htm). For
reasons similar to those that apply to PEP studies, an adequately powered interventional
study for nPEP is unlikely to be performed. Given that there is no evidence that one
particular group of drugs is more effective than others, selection is based on patient-specific
issues and prescriber experience. Preferred regimens include two nucleoside analogs (3TC
or FTC with ZDV or TDF) with lopinavir/ritonavir or efavirenz.
The timing of initiation of prophylaxis is critical to nPEP. From the timeline of mucosal
infection developed from animal and in vitro models (Figure 2), a 24-h window of
protection may be optimal for intervention. The Centers for Disease Control and Prevention
recommendation of 28 days of treatment initiated within 72 h of exposure is supported by
studies in animals. Maximum protection from infection in macaques given high-dose
subcutaneous TFV (30 mg/kg/day) is obtained when treatment is initiated within 24 h of
exposure and continued for 28 days.42 Delaying treatment by 48 or 72 h after exposure and
then continuing treatment for 28 days was <20% effective at protection. If treatment was
started within 24 h but stopped after 10 days, the treatment was only 50% effective. If
treatment was started within 24 h and stopped after 3 days, the treatment was completely
ineffective.
CURRENT APPROACHES TO TREATMENT OF THE INDEX CASE
The model for sustaining an epidemic has been applied to HIV infection.44 The
requirements to sustain an epidemic are summarized in the mathematical equation R0 =
βΔC. R0 is defined as the number of secondary individuals infected by a single infected
person. β is the transmission probability per exposure (including the size/concentration of
the inoculum), Δ is the length of time an individual remains infected, and C is the rate at
which the infected individual acquires new partners. According to this model, R0 must be >1
for the HIV epidemic to be maintained. In the absence of a cure for HIV, there is little that
can affect Δ. Although behavioral interventions and education have influenced C to a
degree, β remains the main target that can be manipulated to control the HIV epidemic.
Chakraborty et al. developed a model of sexual transmission in which a logarithmic increase
in the probability of male-to-female HIV transmission occurs with increasing concentrations
of HIV RNA in the semen and numbers of receptors in the cervical tissue.45 These
mathematical formulas help to highlight the potential public health benefit of suppressing
HIV transmission by treating HIV infection. Although local suppression of viral replication
is paramount to reducing infectivity,6 there is no known threshold of HIV RNA
concentration below which a person can be rendered noninfectious. Observational and
prospective studies have suggested that the threshold HIV RNA concentration in blood
could be <3,500 copies/ml (ref. 6). However, similar data for the genital tract are lacking,
largely because of limitations in sample collection and insufficiently sensitive HIV RNA
detection methods. Assays that are able to detect low viral copy numbers require large
sample volumes of genital secretions, often much higher than what is feasible to collect.
Observational studies have demonstrated the ability of ARV therapy to reduce HIV
transmission. A study in Uganda demonstrated that initiation of ARV therapy (drugs not
specified) along with counseling could reduce risk of transmission by ≤98% over 2 years.46
A 6-year study in Rwanda and Zambia involving 2,993 serodiscordant couples observed
only four new infections in the partners of those receiving ARV therapy and 171 infections
in couples that were not treated (odds ratio 0.87, 95% confidence interval 0.79–0.96; ref.
47).
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Mathematical models have also been developed to predict the role of ARV therapy in
reducing transmission.6 These models vary in their predictions depending on the
assumptions regarding the number needed to be treated, the infectivity of the HIV-positive
individuals, and the ability of ARVs to suppress HIV RNA. Although some of these models
suggest that widespread use of preventive ARV therapy would curb the epidemic, others are
of the opinion that, given the likely sexual disinhibition and increase in HIV resistance as a
result of such preventive therapy, any benefit would be negated.6 Acutely infected
individuals have high viral shedding from the genital tract, often before HIV RNA is
detected in blood. Given that these individuals may be responsible for a significant
proportion of new HIV infections, targeting this cohort for early testing and treatment may
make an important contribution to public health.
The optimal choice of ARVs for “sterilization” of the genital tract has yet to be determined.
Drug exposure in the female genital tract is reviewed elsewhere in this article (see “Current
Approaches to PrEP of HIV Infection”). As is the case in the female genital tract, there is
differential penetration of ARVs in the male genital tract as well.29,31,48–51 Nucleoside
analogs (abacavir: ABC, ZDV, TDF, and 3TC) achieve exposures in semen ranging from
150 to 600% of those observed in blood plasma.29 After oral administration of TDF,
intracellular mononuclear TVF-DP concentrations in the semen are at least eight times
higher than in peripheral blood mononuclear cells.48 However, this increased extracellular–
intracellular relationship with respect to concentration levels in semen does not hold for
ZDV or 3TC. Despite four- to sixfold higher concentrations in seminal plasma, intracellular
mononuclear cell concentrations of ZDV-TP in semen are 40% of those in peripheral blood
mononuclear cells, and mononuclear cell concentrations of 3TC-TP in semen are
approximately equal to those in peripheral blood mononuclear cells.51 As in the female
genital tract, there are no data regarding intrasubject pharmacokinetic variability in the male
genital tract. However, intersubject variability in drug exposure is generally greater in the
male genital tract (the coefficients of variation range from ~100 to 300%) than in blood
plasma. These data illustrate the importance of quantifying intracellular drug exposure to
develop accurate pharmacokinetic–pharmacodynamic models of HIV prevention.
The pharmacokinetics of newer classes of ARVs have recently been evaluated in semen.
The AUC of maraviroc in semen is 40% lower than in blood plasma. However, similar to
findings in the female genital tract, low protein binding in semen results in free drug
concentrations 28-fold higher than the protein-free 90% inhibitory concentration.31
Raltegravir concentrations are 3–6 times higher in semen than in blood plasma;49 however,
the protein binding in seminal plasma has not been determined. A summary of ARV
exposure in relevant mucosal fluids and tissues is presented in Table 2.
An important consideration for choosing ARVs for HIV prevention is genital tract
compartmentalization. Genotypic differences have been found in HIV isolated from blood
plasma and the male and female genital tracts, and this constitutes evidence of viral
compartmentalization.52,53 These resistance patterns coincide with observed ARV drug
exposure in genital secretions. For example, protease inhibitors have the poorest penetration
into the genital tract. This may explain the presence of protease-resistant viral isolates in
seminal plasma and vaginal fluid.29 Likewise, an increased number of mutations conferring
resistance to NNRTIs have been detected in the genital tracts of treatment-experienced
women: for instance, <1% of the efavirenz (an NNRTI) exposure observed in blood plasma
is achieved in CVF.32 Although not adequately tested, it is assumed that ARVs with a higher
exposure in the genital tract will be more effective at reducing viral loads in the genital
compartments. Understanding drug penetration into the genital tract will allow for educated
choices for therapy aimed at “sterilizing” the tract.7
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In January 2008, an international debate followed the release of a consensus statement by
Swiss HIV experts declaring that an HIV-infected person on effective ARV therapy (defined
as suppressed viremia for ≥6 months) with no other sexually transmitted infections may be
considered noninfectious. The statement sparked much concern because of its implications
with respect to behavioral practices of HIV-infected individuals. A model-based analysis of
transmission risk per exposure type demonstrated that, although the risk of transmission in
the setting of effective treatment was decreased, it was not nonexistent and that risky
behaviors should be discouraged.54 HPTN 052 is the first prospective trial designed to
evaluate the use of ARVs in reducing HIV transmission (http://www.hptn.org). This phase
III, two-arm, international study will compare the infection rates related to two different
treatment strategies in serodiscordant couples. This trial is currently enrolling couples in
which the infected partner begins ARV therapy (with a recommended regimen of 3TC +
ZDV + efavirenz or atazanavir) either immediately or when he/she has two consecutive
CD4+ cell counts below 250 mm3, or develops an AIDS-defining illness. Approximately
1,750 couples are being followed for 60 months, and the results are expected in 2013.
DEVELOPMENTAL OBSTACLES IN HIV PREVENTION STUDIES
All current clinical trials for HIV prevention are evaluating TDF, alone or in combination
with FTC. These were chosen on the basis of safety, availability, and preliminary data from
nonhuman primates. Because preclinical pharmacology was not prospectively or
concomitantly performed for the effective subcutaneous doses ranging from 22 to 30 mg/kg
in macaques, standard, labeled treatment dosing strategies were pursued for the clinical
studies. This approach has a number of limitations in HIV prevention research, and more
data are required to make rational choices for drugs, doses, and dosing strategies.
Quantifying the pharmacokinetics of ARVs in mucosal tissues is complex. Concentrations
of the drugs in blood plasma do not always correlate with those in the genital tract and
rectum, and accumulation ratios vary between and within therapeutic classes.29,31,32 The
mechanisms that underlie these differences have yet to be fully elucidated. In the male
genital tract, the primary influence appears to be protein binding. However, as illustrated in
Figure 3, this is not the case for the female genital tract. Further investigations on the
physicochemical properties of ARVs that are associated with increased mucosal penetration
are required.
Although the majority of ARVs act intracellularly, only the NRTIs require further
phosphorylation in order to exert antiviral activity. Limitations in analytical chemistry
detection technology and tissue or cell sampling logistics have precluded quantification of
these active metabolites in the female genital tract. In view of the fact that an extracellular–
intracellular disconnect with respect to ZDV, 3TC, and TFV has been found between semen
and blood,48,51 quantifying these exposures in the female genital tract will be important for
identifying appropriate concentration targets for HIV prevention. Further, quantification of
the intersubject variability in subpopulations of mononuclear cells susceptible to HIV
infection may also provide insight into the probability of protection in a targeted population.
Finally, additional insight is required into the part(s) of the female genital tract (i.e., vagina,
cervix, or uterus) that may be most susceptible to HIV infection and the part(s) that can
serve as a pharmacologic and virologic surrogate for the others. Advanced physiology-based
modeling may be able to assist in this effort.
Developing a reliable animal model for prevention studies has been a challenging task. HIV
infection is a species-specific disease, and this limits the flexibility afforded by animal
models. For decades, research has been limited to macaque models, which permit the study
of SIV, a virus similar to, but not identical with, HIV. SIV’s distinct characteristic with
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respect to co-receptor usage can confound the results of prevention studies.55 SIVmac and
SIVmc most closely resemble HIV-1 in progression of plasma RNA and CD4 T-cell
response.7 The chimeric SHIV, although containing a portion of the HIV-1 genome, does
not mimic the progression of infection as closely as SIV does. Some models utilize
progesterone therapy to thin the epithelial layer of the vaginal tract, increase the probability
of infection, and increase the likelihood of documenting an ARV effect. However, the
impact of this intervention on ARV concentrations or efficacy in these tissues is unknown.
Finally, exposure models also differ. The low-dose repeat-exposure model was developed to
mimic the human condition. The single high-dose exposure model represents the “worst case
scenario.” However, one investigation using oral TDF (22 mg/kg) for PrEP found less
protection with the low-dose exposure model (40%) than with the high-dose model (75%).56
The variability between these models is a strong consideration for assessing outcomes.
Interspecies scaling of ARV exposures between macaques and humans has been difficult
given the limited amount of pharmacokinetic information generated in these studies. The
only systemic ARV regimens that have demonstrated full protection against rectal, vaginal,
and oral exposure to SHIV in macaques are daily or intermittent subcutaneous
administration of 22 mg/kg TFV or 22 mg/kg TFV + 20 mg/kg FTC.13,38 Although no Cmax
or AUC value was reported for subcutaneous TFV, the Cmax of the selected human-
equivalent oral dose (633 ng/ml)37 was approximately twice as high as the observed Cmax in
humans.32 Local exposure of ARVs in mucosal tissues after topical administration remains
to be measured comprehensively in animal models. Given the smaller genital and rectal
cavities of macaques, it is possible that animals in the preclinical trials discussed above
received supratherapeutic dosing.
The humanized mouse model has recently been developed to overcome some of the
logistical challenges associated with macaque models. The first humanized mouse was from
a severe combined immunodeficiency (SCID) variant. The mutation in the prkdc gene
leading to loss of function in mature T and B lymphocytes allows these mice to be infected
with foreign tissue without rejection.14 Because only the implanted tissues can be infected
with HIV, this has limited applications for HIV prevention research. The SCID-hu
peripheral blood lymphocyte model was developed by intraperitoneal injection of human
peripheral blood lymphocytes. Although populations of human B and T cells can be
recovered, the repertoire is limited and transient, with no renewal capacity. These mice have
been used for studying viral pathogenesis and screen vaccine candidates. However, the
limited numbers of human cells in mucosal tissues make them poor candidates for
prevention research. In the SCID-hu Thy/Liv model, human thymus and liver are grafted
into the SCID mouse, with subsequent production of human mononuclear cells (including
CD4+ cells). However, this model is not susceptible to mucosal transmission of HIV, given
that the T cells appear to be confined mostly to the area of the thymus. More recent models
such as the Rag2−/− IL2Rγc−/− , the NOD/SCID-IL2Rγc−/−, and the NOD/SCID BLT mice
generally have more extensive humanization of mucosal tissues. Rag2−/− IL2Rγc−/− mice
are developed by intrahepatic placement of human CD34+ hematopoietic stem cells, which
then differentiate into human B, T, and dendritic cells. These mice are susceptible to HIV
after systemic, vaginal, or rectal exposure. Additionally, appropriate viral suppression and
CD4+ T-cell recovery can be achieved by administering ARV therapy.57 The NOD/SCID-
IL2Rγc−/− mice are generated by the introduction of CD34+ hematopoietic stem cells, either
intrahepatically or intravenously. This model is currently undergoing investigations
regarding its susceptibility to mucosal transmission of HIV. In the NOD/SCID BLT mouse,
human fetal liver and human fetal thymus are implanted under the kidney capsule of the
NOD/SCID mouse, with subsequent transplantation of human fetal liver CD34+
hematopoietic stem cells. This model has shown a robust humanization of the rectal and
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female genital tracts and susceptibility to both vaginal and rectal HIV transmission.14
However, no pharmacokinetic investigations have been performed in this model.
An alternative, or complementary, approach to a preclinical animal model for HIV
prevention strategies is the tissue explant culture model. This technique has been previously
used with human thymus tissue and has more recently been applied in rectal, vaginal, and
cervical tissues, which are the common sites of exposure in HIV transmission.58 This
promising ex vivo approach allows human tissue from healthy volunteers to be used in the
study of HIV transmission as well as ARV safety, efficacy, and pharmacology. Insights into
successful prevention strategies may be obtained by varying drug doses, viral isolates, and
titers in this model. This technique has been utilized to evaluate several candidate
microbicides.19,20,22,25
FUTURE ROLE OF CLINICAL PHARMACOLOGY IN BRIDGING THE GAPS
As more predictive preclinical models are developed for prevention, the tools of
pharmacology will become a valuable resource for determining pharmacodynamic targets,
providing interspecies scaling of exposures, identifying the optimal drugs/drug
combinations, doses, and dosing regimens, and designing efficient clinical trials.
Characterization of the pharmacokinetics occurring at mucosal surfaces that are prone to
infection (rectal, vaginal, and cervical) has provided valuable information about the ARVs
that should be further investigated in prevention trials. The drugs that accumulate in tissues
(e.g., TFV, FTC, 3TC, and maraviroc), as well as those that achieve concentrations above
their respective 90% inhibitory concentration values (e.g., raltegravir, atazanavir, and
darunavir) are candidates for further investigation. However, the specific pharmacokinetic
behavior of these drugs in tissues, including residence times, cellular uptake, and
intracellular phosphorylation, remains unknown. Although it is known that certain
physiochemical properties such as protein binding, lipophilicity, and molecule size have an
impact on the drug’s penetration into genital tract secretions, the mechanisms of uptake
remain undefined, particularly for the female genital tract. Even without a complete
mechanistic understanding of drug movement between these compartments,
pharmacokinetic modeling may still allow for accurate estimation of concentrations in the
genital tract.
The recent results from the Caprisa 004 trial demonstrate the importance of incorporating
robust pharmacology sampling into future prevention trials. Using CVF concentrations, a
compelling trend was established between higher TNF CVF concentration and lower HIV
infection rates. A similar trend was noted with lower HSV2 infection rates, Particularly
when concentrations were higher than the TNF in vitro IC50 for HSV2 of approximately
10,000 μg/ml.59 Based on these data, it’s clear that including detailed pharmacokinetic
samping at the site of infection in HIV prevention trails will allow for the determination of
pharmacologic targets for protection.
It is critical to determine the concentration of ARVs needed at the site of exposure to
prevent HIV infection. Preclinical models have shown that ARVs can protect against HIV
infection. However, in the absence of rigorous pharmacokinetic data, it is difficult to
determine how these results can be extrapolated to humans. More focused, well-designed
sampling strategies in preclinical models can provide a great deal of information with only
minimal increase in cost and effort. The tissue explant culture model may also assist in
defining pharmacokinetic–pharmacodynamic relationships in cervical, vaginal, and rectal
mucosal tissues. Physiology-based modeling may then assist in selecting the most
appropriate drugs or combinations, doses, and dosing strategies to move forward in clinical
investigations.
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Once drug targets for prevention are identified, determining the appropriate surrogate
sampling schemes for generating data in large groups of individuals will be required. Figure
4 represents the compartments from which pharmacokinetic data can be obtained. It is
possible that only intracellular ARV concentrations from a specific cellular subset in tissues
predict efficacy. However, in order to expediently perform larger population
pharmacokinetic–pharmacodynamic modeling analysis from registered clinical trials,
surrogates for this exposure will need to be developed. However, optimal use of these
surrogates requires accurate information related to the time points at which the interventions
are used. Without proper dose-timing information, any drug exposure measure will have
little value as a tool for assessing adherence to dosing regimens.
Likewise, when comparing local exposures in the mucosal tissues to blood plasma
concentrations, single paired concentrations will not yield as comprehensive an
understanding of drug exposure as AUC measurements. In order to calculate an AUC,
however, one requires either extensive intraindividual sampling or pharmacokinetic models
with population pharmacokinetic approaches. This is why many of the clinical trials
conducted to date have not prospectively incorporated this degree of pharmacokinetic
sampling. Future studies with a more considered approach to obtaining pharmacokinetic
data will provide additional insight into the pharmacologic relationships among dose, drug
concentrations in plasma, drug concentrations in mucosa, and the efficacy of the treatment.
Finally, an important consideration in analyzing clinical trial data is the confounder of
adherence to therapy. In the case of prevention research, reliance is placed on the individual
subjects to ensure adherence to the therapeutic regimen. In order to adequately interpret
clinical trial outcomes, investigators require a thorough understanding of the number of
subjects in the active treatment arm who are not taking their medications, and the number of
subjects in the placebo arm who are being exposed to the drug (e.g., as a result of drug
pooling/sharing). Having too many of these subjects in each group has the potential to
confound the results and negate the time and resources invested in the clinical trial. Real-
time pharmacokinetic sampling with subsequent adherence interventions could be built into
these investigations for pharmacologic quality assurance. HPTN 066 is the first study
designed specifically to build a pharmacokinetic model to address this issue in subsequent
prevention studies.
CONCLUSION
The recent failures with microbicide and vaccine candidates for HIV prevention necessitate
a focus on topical and systemic ARV therapy. Implementation of an acceptable and
efficacious ARV prevention strategy will dramatically affect the global HIV epidemic and
significantly reduce the burden of disease. Both topical and systemic use of ARVs in animal
models have produced promising data. From these data, a number of prevention studies were
created to investigate a limited range of ARVs in a variety of populations and geographic
settings (as of this year, nearly 20,000 individuals will be enrolled in PrEP trials). Because
these current clinical trials were not designed to provide definitive information to correlate
drug exposure with HIV protection, many pharmacologic opportunities still exist. The target
ARV exposure for prevention of infection in animals or tissues is unknown, as is the effect
of combining ARVs from different drug classes. New analytical capabilities and novel
sampling strategies allow cellular pharmacokinetics and dynamics to be more diligently
investigated and to identify surrogate markers for protection. Assessing the proportionality
between intracellular and mucosal tissue concentrations of drugs will allow the development
of predictive pharmacokinetic–pharmacodynamic models to investigate strategies for
intermittent PrEP at suitable dosages that are most likely to succeed. Standardization of real-
time drug adherence/exposure measures in clinical studies will ensure interpretable results
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once studies are complete. The tools, techniques, and expertise of clinical pharmacology are
essential to advancing the field of HIV prevention and will continue to play a significant role
until the HIV epidemic can be contained.
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Opportunities for prevention. PEP, postexposure prophylaxis; PrEP, pre-exposure
prophylaxis.
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Timeline of mucosal infection. ARV, antiretroviral.
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Relationship of total genital tract exposure to blood plasma protein binding. 3TC,
lamivudine; ABC, abacavir; APV, amprenavir; ATV, atazanavir; AZT, zidovudine; D4T,
stavudine; DDI, didanosine; DLV, delavirdine; EFV, efavirenz; FTC, emtricitabine; IDV,
indinavir; LPV, lopinavir; MVC, maraviroc; NVP, nevirapine; RTV, ritonavir; SQV,
saquinavir; TNF, tenofovir.
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What should be measured for accurate pharmacokinetic–pharmacodynamic evaluations?
*Only nucleoside/tide analog reverse-transcriptase inhibitors require phosphorylation for
activation. ARV-P-P-P = tri-phosphorylated metabolite; fub = fraction of drug that is
unbound from protein.
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Table 2







Drug CVF Tissue Seminalplasma Intracellular Tissue
NRTIs
Tenofovir 1.7 4.0e/0.6f,g 4.4 (5.1)b 9.4 (17.5)b 33g
Abacavir 0.7 0.4 1.5
Lamivudine 16 4.0 6.0 1.0
Zidovudine 11 1.9 2.0 0.4
Didanosine 2.1 1.0
Emtricitabine 6.2 42e,g/7f,g 6.0 ND 4.4g
Stavudine 0.04 0.04 0.02
PIs
Lopinavir 0.04 0.3 0.05
Atazanavir 0.17 0.3 0.1











Maraviroc 1.9 (2.7)b,c (1.9)c 0.6 c 9 (28)b,c
Integrase Inhibitors
Raltegravir 1.0 3.2
Comparisons are between tissue/BP-paired samples after a single dose unless otherwise noted.
AUC, area under the concentration–time curve; BP, blood plasma; CVF, cervicovaginal fluid; NNRTI, non–nucleoside analog reverse-transcriptase












AUC tissue0–14 days:AUC BP0–14 days.
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